Companies / Lb Pharmaceuticals Inc

Lb Pharmaceuticals Inc

Nasdaq: LBRXCIK 1691082NEW YORK, NY

Financials

Revenue
Net income$-25.20M
Total debt
Cash$283.11M
Diluted EPS$-3.13
Shares outstanding32.3M

Ownership

32.3M shares outstanding · as of Aug 5, 2026
11.9%10%+ / strategic
Ownership
10%+ / strategic11.94%3,850,416
Institutions68.19%21,996,722
Public float19.88%6,412,037

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Kroin David10% owner

Institutional holders 77

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jun 3, 2026Ruffolo Robert R
Director
GrantStock Option (Right to Buy)+10K
10,000
0.03% of shares
low
Mar 6, 2026Lenz Robert A.
Director
GrantStock Option (Right to Buy)+20K
20,000
0.06% of shares
low
Feb 6, 2026Deep Track Biotechnology Master Fund, Ltd.
10% owner
BuyPre-Funded Warrants (Right to Buy)+94K
93,925
0.29% of shares
low
Feb 6, 2026Deep Track Biotechnology Master Fund, Ltd.
10% owner
BuyPre-Funded Warrants (Right to Buy)+378K
378,444
1.17% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
RA Capital Management, L.P.Passive13G/A
BlackRock Portfolio Management LLCPassive13G/A961,158
JPMORGAN CHASE & COPassive13G1,611,482
BlackRock, Inc.Passive13G1,277,776

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
LBRXCommon StockEquity50180M108BBG00XNP5MQ4